𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bevacizumab plus irinotecan in recurrent malignant glioma. Our experience

✍ Scribed by García Cabezas, S.; Serrano Blanch, R.; Romeo Olmedo, J.; Aranda Aguilar, E.; Palacios Eito, A.

Book ID
123288969
Publisher
Wielkopolskie Centrum Onkologii
Year
2013
Tongue
Polish
Weight
69 KB
Volume
18
Category
Article
ISSN
1507-1367

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of irinotecan plus celeco
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
✍ David A. Reardon; Jennifer A. Quinn; James Vredenburgh; Jeremy N. Rich; Sridhara 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

## Abstract ## BACKGROUND In the current study, the authors report a Phase II trial of irinotecan (CPT‐11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX‐2 inhibitor, among MG patients with recurrent disease. ## METHODS Patients with MG at any